Aura Biosciences Reports First Quarter 2024 Financial Results and Business Highlights
May 09, 2024 07:00 ET
|
Aura Biosciences, Inc.
Continued Enrollment in Global Phase 3 CoMpass Trial in Small Choroidal Melanoma and Indeterminate Lesions Ongoing Phase 1 Trial in Bladder Cancer Enrolling; Early Data Expected Mid-2024 Strong...
Aura Biosciences to Participate in Upcoming Investor Conferences
May 08, 2024 07:00 ET
|
Aura Biosciences, Inc.
BOSTON, May 08, 2024 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision immunotherapies to treat solid tumors designed to preserve...